Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Burns

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Nature Chemical Biology|June 18, 2016
Chromatin targeting: A BET inhibitor workaroundChristopher J Burns
BMJ (Clinical Research Ed.)|September 15, 2011
Doctors and torture in Israel. Why the secrecy?Christopher J Burns-Cox
Expert Opinion on Therapeutic Patents|January 6, 2011
c-FMS inhibitors: a patent reviewChristopher J Burns, Andrew F Wilks
Clinics in Colon and Rectal Surgery|February 2, 2010
Venous thromboembolic disease in colorectal patientsMichael P McNally, Christopher J Burns
Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
The Use of JAK-specific inhibitors as chemical biology toolsChristopher J Burns, David Segal, Andrew F Wilks
Current Stem Cell Research & Therapy|January 29, 2008
Diabetes mellitus: a potential target for stem cell therapyChristopher J Burns, Shanta J Persaud, Peter M Jones
The Journal of Endocrinology|December 14, 2004
Stem cell therapy for diabetes: do we need to make beta cells?Christopher J Burns, Shanta J Persaud, Peter M Jones
Pancreas|December 19, 2009
Importance of quantitative analysis in the generation of insulin-expressing cells from human embryonic stem cellsMonica L Courtney, Peter M Jones, Christopher J Burns
Expert Opinion on Therapeutic Patents|November 23, 2013
BET bromodomain inhibitors: a patent reviewJean-Marc Garnier, Phillip P Sharp, Christopher J Burns
Drug Discovery Today|July 26, 2008
Cell-based treatments for diabetesPeter M Jones, Monica L Courtney, Christopher J Burns, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Nature Chemical Biology|June 18, 2016
Chromatin targeting: A BET inhibitor workaroundChristopher J Burns
BMJ (Clinical Research Ed.)|September 15, 2011
Doctors and torture in Israel. Why the secrecy?Christopher J Burns-Cox
Expert Opinion on Therapeutic Patents|January 6, 2011
c-FMS inhibitors: a patent reviewChristopher J Burns, Andrew F Wilks
Clinics in Colon and Rectal Surgery|February 2, 2010
Venous thromboembolic disease in colorectal patientsMichael P McNally, Christopher J Burns
Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
The Use of JAK-specific inhibitors as chemical biology toolsChristopher J Burns, David Segal, Andrew F Wilks
Current Stem Cell Research & Therapy|January 29, 2008
Diabetes mellitus: a potential target for stem cell therapyChristopher J Burns, Shanta J Persaud, Peter M Jones
The Journal of Endocrinology|December 14, 2004
Stem cell therapy for diabetes: do we need to make beta cells?Christopher J Burns, Shanta J Persaud, Peter M Jones
Pancreas|December 19, 2009
Importance of quantitative analysis in the generation of insulin-expressing cells from human embryonic stem cellsMonica L Courtney, Peter M Jones, Christopher J Burns
Expert Opinion on Therapeutic Patents|November 23, 2013
BET bromodomain inhibitors: a patent reviewJean-Marc Garnier, Phillip P Sharp, Christopher J Burns
Drug Discovery Today|July 26, 2008
Cell-based treatments for diabetesPeter M Jones, Monica L Courtney, Christopher J Burns, et al.
Pageof 7